tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine Biosciences Launches Phase 2 Trial for Bipolar I Disorder Treatment
Company AnnouncementsNeurocrine Biosciences Launches Phase 2 Trial for Bipolar I Disorder Treatment
4d ago
NBIX
Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 2a Clinical Study
PremiumCompany Announcements
Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 2a Clinical Study
4d ago
NBIX
Neurocrine’s Strategic Growth and Innovation: Analyst Upgrades Price Target to $198 with Buy Rating
PremiumRatings
Neurocrine’s Strategic Growth and Innovation: Analyst Upgrades Price Target to $198 with Buy Rating
4d ago
NBIX
Neurocrine price target raised to $198 from $168 at H.C. Wainwright
PremiumThe Fly
Neurocrine price target raised to $198 from $168 at H.C. Wainwright
4d ago
NBIX
Neurocrine Biosciences: Strong R&D Pipeline and Strategic Advancement in Neuropsychiatry and Obesity Treatment
PremiumRatings
Neurocrine Biosciences: Strong R&D Pipeline and Strategic Advancement in Neuropsychiatry and Obesity Treatment
4d ago
NBIX
Buy Rating: Unlocking Neurocrine Biosciences’ Long-Term Growth Potential Through Diversified Pipeline
PremiumRatingsBuy Rating: Unlocking Neurocrine Biosciences’ Long-Term Growth Potential Through Diversified Pipeline
4d ago
NBIX
Neurocrine’s Strategic Pipeline Positions for Growth in Addressing Unmet Medical Needs
Premium
Ratings
Neurocrine’s Strategic Pipeline Positions for Growth in Addressing Unmet Medical Needs
4d ago
NBIX
Neurocrine Biosciences: Driving Innovation with Ambitious R&D Goals and Promising Pipeline Advancements
Premium
Ratings
Neurocrine Biosciences: Driving Innovation with Ambitious R&D Goals and Promising Pipeline Advancements
4d ago
NBIX
Neurocrine Biosciences: A Strategic Leap in Innovation and Pipeline Diversification
PremiumRatings
Neurocrine Biosciences: A Strategic Leap in Innovation and Pipeline Diversification
4d ago
NBIX
Neurocrine Biosciences Launches Phase 3 Study on Schizophrenia Relapse Prevention
PremiumCompany Announcements
Neurocrine Biosciences Launches Phase 3 Study on Schizophrenia Relapse Prevention
7d ago
NBIX
Neurocrine price target raised to $175 from $146 at Mizuho
PremiumThe Fly
Neurocrine price target raised to $175 from $146 at Mizuho
9d ago
NBIX
Neurocrine price target raised to $188 from $183 at Stifel
PremiumThe Fly
Neurocrine price target raised to $188 from $183 at Stifel
10d ago
NBIX
Neurocrine price target raised to $180 from $160 at RBC Capital
PremiumThe FlyNeurocrine price target raised to $180 from $160 at RBC Capital
13d ago
NBIX
TEVA
Neurocrine price target raised to $200 from $175 at TD Cowen
Premium
The Fly
Neurocrine price target raised to $200 from $175 at TD Cowen
16d ago
NBIX
Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
Premium
Ratings
Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
25d ago
NBIX
Neurocrine Extends Eiry W. Roberts’ Employment Term
PremiumCompany Announcements
Neurocrine Extends Eiry W. Roberts’ Employment Term
27d ago
8K
NBIX
Neurocrine’s Promising Prospects: Buy Rating Backed by Osavampator’s Success and Ingrezza’s Revenue Growth
PremiumRatings
Neurocrine’s Promising Prospects: Buy Rating Backed by Osavampator’s Success and Ingrezza’s Revenue Growth
1M ago
NBIX
Neurocrine price target lowered to $173 from $178 at Morgan Stanley
PremiumThe Fly
Neurocrine price target lowered to $173 from $178 at Morgan Stanley
1M ago
NBIX
Neurocrine’s Growth Potential and Positive Outlook Justify Buy Rating Despite Setbacks
PremiumRatings
Neurocrine’s Growth Potential and Positive Outlook Justify Buy Rating Despite Setbacks
1M ago
NBIX
Promising Growth Prospects for Neurocrine: Buy Rating Reaffirmed Despite Setbacks
PremiumRatingsPromising Growth Prospects for Neurocrine: Buy Rating Reaffirmed Despite Setbacks
1M ago
NBIX
Neurocrine says Phase 2 study of NBI-1070770 did not meet primary endpoint
Premium
The Fly
Neurocrine says Phase 2 study of NBI-1070770 did not meet primary endpoint
1M ago
NBIX
Neurocrine price target raised to $179 from $171 at JPMorgan
Premium
The Fly
Neurocrine price target raised to $179 from $171 at JPMorgan
2M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >